Related Experiment Video
Updated: Jun 21, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Management of cardiogenic shock: focus on tissue perfusion
Insights
Cardiogenic shock (CS) is a critical condition with high mortality, often following heart attacks. Aggressive heart support and optimizing tissue perfusion are vital for improving outcomes in CS patients.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock (CS) is a primary cause of in-hospital mortality in acute myocardial infarction patients.
- Despite advances like early revascularization, CS mortality remains high, with similar long-term risks for survivors compared to non-shock myocardial infarction patients.
Purpose of the Study:
- To review current treatments for cardiogenic shock.
- To highlight novel bedside monitoring and modulation techniques for peripheral circulation in CS management.
Main Methods:
- Literature review of current cardiogenic shock management strategies.
- Evaluation of emerging technologies for peripheral circulation assessment and intervention.
Main Results:
- Cardiogenic shock management requires a dual approach: enhancing cardiac function and optimizing tissue perfusion.
- Novel monitoring techniques show promise for guiding CS therapy.
Conclusions:
- Aggressive acute-phase support is crucial for patients with cardiogenic shock.
- Improved understanding and application of monitoring technologies may enhance long-term prognosis for CS survivors.
Abstract:
Cardiogenic shock (CS) may result from ischemic heart disease, cardiomyopathy, valvular heart disease, inflammation, myocardial contusion, and cardiac surgery. CS is the leading cause of in-hospital death in patients with acute myocardial infarction. Although early revascularization strategies have resulted in a better prognosis, in-hospital mortality from CS remains exceptionally high. Notably, long-term annual mortality is similar in survivors of CS relative to patients with myocardial infarction without shock. This underlines the importance of aggressive support of the failing heart in the acute phase of CS. Because CS reflects a state of hypoperfusion induced by heart failure, management of CS should aim at improving cardiac function as well as at optimization of tissue perfusion. This review evaluates the current treatment of CS. In addition, novel approaches to monitor and modulate peripheral circulation at the bedside are highlighted. It is expected that these techniques will improve our understanding of the pathogenesis of CS and will offer new opportunities to guide therapy in CS patients to improve long-term prognosis.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Aortic Regurgitation IV: Nursing Management
Pericarditis IV: Nursing Management
Heart Failure V: Medical Management
Acute Coronary Syndrome IV: Interprofessional Care
